Global team to study international differences in COVID-19 immunity
Supported by £3.1 million from the Wellcome Trust, the newly-created WWW Consortium links three leading studies in West Africa (Yemaachi Biotech Heritage Study), the West Indies (Windfall Study in Kingston, Jamaica), and West London (the Legacy Study), each tracking how both the virus and our immunity has evolved against COVID-19.
African biotech holds the key to transforming not just the health of African people, but our economies as well
Why has over a decade of political rhetoric and unprecedented donor support for scientific capacity building not translated into more tangible scientific output?
A closer look reveals a glaring gap in the current structure of the scientific ecosystem in Africa – the almost complete absence of the private sector.
Ghana startup strives for greater African representation in cancer research
As one of Ghana’s only labs equipped for molecular analysis, Bediako’s team have tasked themselves with collecting data they believe will advance the development of medicine for cancer patients throughout the continent and diaspora
Yemaachi, Africa’s Cancer Research Company, Raises Seed Round To Diversify Genomic Datasets & Advance Precision Oncology Globally
Yemaachi Biotech announced today the close of a $3 million seed round to advance its mission of diversifying precision oncology globally. V8 Capital led the round, with LifeLine Family Heritage Fund, Y Combinator, Tencent, LoftyInc Capital, VestedWorld, V Square Capital and Ethan Perlstein also participating.
Yemaachi Biotech, Lucence Aim to Improve Genomic Breast Cancer Testing in Ghana and Beyond
GenomeWeb covers Yemaachi’s collaboration with cancer liquid biopsy firm Lucence to document and characterize the genomics of breast cancer in women of African descent.
H3D Partners with Yemaachi to Utilise African Genetic Diversity to Develop New Tools for Improving Treatment Outcomes for the African Patient Populations
The Holistic Drug Discovery and Development (H3D) Centre at the University of Cape Town (UCT) has entered into a strategic partnership with Yemaachi Biotech, to exploit African genetic diversity by identifying new therapies and platforms that optimize cancer treatments for African patient populations.